Abstract
Aims: Design of sulfonamide-triazine derivatives as JAK1 inhibitors. Background: JAK1 is a kinase involved in different autoimmune diseases. JAK1 inhibitors have shown promising results in treating autoimmune diseases.
Objectives: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.
Methods: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.
Results: Nineteen compounds have been prepared, some of which exhibited low micromolar IC50 values against JAK1.
Conclusions: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.
Keywords: JAK1 inhibitors, sulfonamides, diamino-triazines, docking, dose-response, crystallographic complexes.
Graphical Abstract
Current Computer-Aided Drug Design
Title:Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates
Volume: 17 Issue: 7
Author(s): Safa Daoud and Mutasem O. Taha*
Affiliation:
- Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan
Keywords: JAK1 inhibitors, sulfonamides, diamino-triazines, docking, dose-response, crystallographic complexes.
Abstract: Aims: Design of sulfonamide-triazine derivatives as JAK1 inhibitors. Background: JAK1 is a kinase involved in different autoimmune diseases. JAK1 inhibitors have shown promising results in treating autoimmune diseases.
Objectives: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.
Methods: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.
Results: Nineteen compounds have been prepared, some of which exhibited low micromolar IC50 values against JAK1.
Conclusions: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.
Export Options
About this article
Cite this article as:
Daoud Safa and Taha O. Mutasem *, Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates, Current Computer-Aided Drug Design 2021; 17 (7) . https://dx.doi.org/10.2174/1573409916666201224152253
DOI https://dx.doi.org/10.2174/1573409916666201224152253 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Lipid-Protamine-DNA-Mediated Antigen Delivery
Current Drug Delivery Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates
Current Pediatric Reviews Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Liver-Related Factors Associated with Low Vitamin D Levels in HIV and HIV/HCV Coinfected Patients and Comparison to General Population
Current HIV Research CD8+ T-Cells: Function and Response to HIV Infection
Current HIV Research Safer, Greener, and More Facile Alternatives for Synthesis with Organic Azides
Current Organic Synthesis Novel Spiro/non-Spiro Pyranopyrazoles: Eco-Friendly Synthesis, In-vitro Anticancer Activity, DNA Binding, and In-silico Docking Studies
Current Bioactive Compounds CD4+ T Cell Responses in the Immune Control Against Latent Infection by Epstein-Barr Virus
Current Molecular Medicine Drug Targets in Hepatitis B Virus Infection
Infectious Disorders - Drug Targets The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Branched-chain Amino Acid Oxidation in Skeletal Muscle – Physiological and Clinical Importance of its Modulation by Reactant Availability
Current Nutrition & Food Science Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications
Current Computer-Aided Drug Design Identification of Enzyme Inhibitors from Phage-Displayed Combinatorial Peptide Libraries
Combinatorial Chemistry & High Throughput Screening